Document is current
Any future updates will be listed below
-
Authors
Zhang, Shangzhu
Xu, Dong
Liu, Shengyun
Li, Shujie
Wang, Xiaoxia
Yuan, Fenghong
Gou, Wei
Xu, Baijie
Sun, Lingyun
Gu, Jieruo
Zhou, Dongmei
Li, Xiaomei
Kong, Ning
Zhao, Yi
Hao, Jie
Li, Tianwang
Fan, Xiaoyun
Shu, Qiang
Wei, Hua
Jiang, Tao
Yang, Jing
Qian, Long
Sun, Hongsheng
Cai, Xiaoyan
Jiang, Zhenyu
Yuan, Guohua
Qin, Li
Yang, Min
Xu, Jian
Fan, Wenqiang
Sun, Li
Zhang, Hua
Zhang, Chunyan
Zhang, Ning
Da, Zhanyun
Hu, Jiankang
Jin, Jingchun
Liu, Ju
Dai, Lie
Dong, Lingli
Wang, Wei
Zeng, Xiaofeng https://orcid.org/0000-0002-3883-2318
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05881785 at ClinicalTrials.govDocuments that mention this clinical trial
Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
https://doi.org/10.1007/s40259-025-00750-0
- License Information
-
More Information
Article History
Accepted: 28 October 2025
First Online: 17 November 2025
Declarations
:
: Wei Wang was an employee of Chongqing Genrix Biopharmaceutical at the time of the study. The other authors have declared no conflict of interest.
: The data that support the findings of this study are not openly available for reasons of sensitivity, but are available from the corresponding author upon reasonable request.
: The study protocol and its amendments were reviewed and approved by the independent ethics committee or Institutional Review Board (IRB) at each center. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki and the Council of International Organizations of Medical Sciences International Ethical Guidelines.
: Written informed consent was obtained from all enrolled patients.
: Not applicable.
: Not applicable.
: All listed authors fulfill the ICMJE authorship criteria, have approved the final version for publication, and accept responsibility for the integrity of the work as a whole. All authors contributed to the study design, data analysis, and interpretation. The first draft of the manuscript was written by Shangzhu Zhang, and all authors commented on previous versions. All authors read and approved the final manuscript.
